(3β)-(3-2H)Cholest-5-en-3-ol

Modify Date: 2024-01-10 17:19:19

(3β)-(3-2H)Cholest-5-en-3-ol Structure
(3β)-(3-2H)Cholest-5-en-3-ol structure
Common Name (3β)-(3-2H)Cholest-5-en-3-ol
CAS Number 51467-57-3 Molecular Weight 387.66
Density 1.0±0.1 g/cm3 Boiling Point 480.6±14.0 °C at 760 mmHg
Molecular Formula C27H45DO Melting Point N/A
MSDS N/A Flash Point 209.3±12.4 °C

 Use of (3β)-(3-2H)Cholest-5-en-3-ol


Cholesterol-d1 is the deuterium labeled Cholesterol. Cholesterol is the major sterol in mammals and is makes up 20-25% of structural component of the plasma membrane. Plasma membranes are highly permeable to water but relatively impermeable to ions and protons. Cholesterol plays an important role in determining the fluidity and permeability characteristics of the membrane as well as the function of both the transporters and signaling proteins[1][2]. Cholesterol is also an endogenous estrogen-related receptor α (ERRα) agonist[3][4].

 Names

Name cholesterol-3-d1
Synonym More Synonyms

 (3β)-(3-2H)Cholest-5-en-3-ol Biological Activity

Description Cholesterol-d1 is the deuterium labeled Cholesterol. Cholesterol is the major sterol in mammals and is makes up 20-25% of structural component of the plasma membrane. Plasma membranes are highly permeable to water but relatively impermeable to ions and protons. Cholesterol plays an important role in determining the fluidity and permeability characteristics of the membrane as well as the function of both the transporters and signaling proteins[1][2]. Cholesterol is also an endogenous estrogen-related receptor α (ERRα) agonist[3][4].
Related Catalog
In Vitro Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
References

[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.

[2]. Casaburi I, et al. Cholesterol as an Endogenous ERRα Agonist: A New Perspective to Cancer Treatment. Front Endocrinol (Lausanne). 2018 Sep 11;9:525.

[3]. Dietschy JM, et al. Thematic review series: brain Lipids. Cholesterol metabolism in the central nervous system during early development and in the mature animal. J Lipid Res. 2004 Aug;45(8):1375-97.

[4]. Fukui K, et al. Effect of Cholesterol Reduction on Receptor Signaling in Neurons. J Biol Chem. 2015 Sep 14.

 Chemical & Physical Properties

Density 1.0±0.1 g/cm3
Boiling Point 480.6±14.0 °C at 760 mmHg
Molecular Formula C27H45DO
Molecular Weight 387.66
Flash Point 209.3±12.4 °C
Exact Mass 387.361145
PSA 20.23000
LogP 9.85
Vapour Pressure 0.0±2.7 mmHg at 25°C
Index of Refraction 1.525

 Synthetic Route

~%

(3β)-(3-2H)Cholest-5-en-3-ol Structure

(3β)-(3-2H)Chol...

CAS#:51467-57-3

Literature: Murari, Martha P.; Murari, Ramaswamy; Baumann, Wolfgang J. Magnetic Resonance in Chemistry, 1985 , vol. 23, # 4 p. 243 - 245

~%

(3β)-(3-2H)Cholest-5-en-3-ol Structure

(3β)-(3-2H)Chol...

CAS#:51467-57-3

Literature: Suginome, Hiroshi; Furusaki, Akio; Kato, Kimitoshi; Maeda, Norio; Yonebayashi, Fumihiko Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1972-1999), 1981 , p. 236 - 250

 Precursor & DownStream

Precursor  1

DownStream  0

 Synonyms

3-deuteriocholesterol
Cholest-5-en-3-d-3-ol, (3β)-
(3β)-(3-H)Cholest-5-en-3-ol
3-2H-cholesterol
<3-Trifluormethyl-phenyl)-<2-hydroxy-aethyl>-thioharnstoff